Abzena subsidiary Antitope, INSERM and Baylor Institute for Immunology Research to collaborate to produce manufacturing cell lines for two vaccines for HIV

14-Jan-2015 - United Kingdom

Abzena plc announced its wholly-owned subsidiary Antitope Limited has extended its relationship with Inserm, ANRS and the Baylor Institute for Immunology Research (“BIIR”.
INSERM-ANRS and the BIIR have developed innovative approaches for HIV vaccines targeting HIV antigens to dendritic cells (DC) using monoclonal antibodies fused to HIV antigens.  Extensive preclinical data has demonstrated the high immunogenicity of the candidate vaccines. Antitope will produce cell lines for GMP manufacture of two anti-CD40-HIV fusion proteins that INSERM-ANRS and BIIR are developing as potential therapeutic and prophylactic vaccines to treat HIV. The cell lines will be produced using Antitope’s Composite CHO™ technology. The antibody component of the fusion proteins has previously been humanized by Antitope using its Composite Human Antibody™ technology. Phase I and Phase II clinical trials will be conducted in France to test the immunogenicity and efficacy of these DC-targeting vaccines developed by INSERM-ANRS in partnership with the BIIR.

Other news from the department science

Most read news

More news from our other portals